AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02858193
Drug: Fluifort® syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments.
Trial: NCT02369029
Drug: BAY 1238097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
Trial: NCT02461121
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/kg/d for 2 days
Trial: NCT00112151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
Trial: NCT01476215
Drug: Paracetamol medium dissolution suspension
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00288587
Drug: IV loop diuretic
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
Trial: NCT02082054
Drug: PSE 120 mg, CM 8 mg, Atr 0.36 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side
Trial: NCT02082054
Drug: PSE 120 mg, CM 8 mg, Atr 0.24 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side
Trial: NCT02082054
Drug: PSE 120 mg, CM 8 mg, Atr 0.12 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side
Trial: NCT02082054
Drug: PSE 120 mg, CM 8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
Trial: NCT04755543
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
Trial: NCT03919890
Drug: ONO-7684 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03990766
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline delivered via high-volume, low-pressure nasal saline irrigation
Trial: NCT00092586
Drug: Comparator: statins
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01869829
Drug: Observational antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care.
Trial: NCT02467452
Drug: BDP/FF/GB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366834
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: casopitant placebo
Trial: NCT01259492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo
Trial: NCT02016417
Drug: A combination of Docetaxel, cisplatin and 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
Trial: NCT00667758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-5 ml NaCl s.c. on days 1-5
Trial: NCT00976768
Drug: oxaliplatin, 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
Trial: NCT02752867
Drug: Jianpi Yishen Huatan Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
Trial: NCT01244334
Drug: Prednisolone acetate 1%
RxNorm normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
Trial: NCT01270672
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules identical to MDMA or carvedilol
Trial: NCT02697955
Drug: Bupivacaine-epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg bupivacaine and 50 μg adrenalin
Trial: NCT01324583
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT03115489
Drug: Traditional Treatment (Group T)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive traditional drug infusions
Trial: NCT01703286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Glimepiride
Trial: NCT01703286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Linagliptin
Trial: NCT03997539
Drug: Treatment of physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
Trial: NCT00958568
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 or 50 mg/day fixed dosing for 27 weeks
Trial: NCT01208896
Drug: Reduced_intensity conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
Trial: NCT02135471
Drug: acellular dermal matrix graft
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
Trial: NCT03108755
Drug: ASP7713
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03108755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01631032
Drug: Qi-tonifying Chinese herbal products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
Trial: NCT03320447
Drug: methyl-aminolevulinate application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
Trial: NCT01234402
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 orally~Twice a day for 14 days
Trial: NCT00019513
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00019513
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01870700
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
Trial: NCT02278276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg capsules containing placebo
Trial: NCT00447863
Drug: Levonorgestrel/Ethinyl Estradiol
RxNorm normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02717871
Drug: Cefazolin in combination with either tobramycin or gentamicin
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).
Trial: NCT02717871
Drug: Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
Trial: NCT02717871
Drug: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
Trial: NCT01204840
Drug: Patch protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped.
Trial: NCT00367640
Drug: 100 IR grass pollen allergen extract tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Trial: NCT00367640
Drug: 300 IR grass pollen allergen extract tablet
RxNorm normalized name: orchard grass pollen extract 300 IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Trial: NCT00367640
Drug: 500 IR grass pollen allergen extract tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Trial: NCT00367640
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Trial: NCT01671488
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
Trial: NCT00520819
Drug: Antioxidant-rich food items
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01106534
Drug: placebo + aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Trial: NCT00887172
Drug: Jing Fang Bai Du san
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
Trial: NCT00887172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
Trial: NCT00887172
Drug: Ying Qiao san
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
Trial: NCT02699281
Drug: ultra-micronized palmitoylethanolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultra-micronized palmitoylethanolamide 600 mg twice a day
Trial: NCT02699281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: um-PEA like placebo twice a day
Trial: NCT04558346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40ug/kg twice daily by self-injection
Trial: NCT02391623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
Trial: NCT03813563
Drug: RL
RxNorm normalized name: Arlex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactated Ringer's
Trial: NCT03719560
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic methotrexate
Trial: NCT00428727
Drug: Controlled nitric oxide releasing patch
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily application of nitric oxide patch during 90 days
Trial: NCT00428727
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily application during 90 days
Trial: NCT02586246
Drug: CDP870
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-injection
Trial: NCT00003342
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04533841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03042013
Drug: ASP8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03464058
Drug: BOS172767 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT03464058
Drug: BOS172767 liquid capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT03464058
Drug: BOS172767 micronized capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT03464058
Drug: BOS172767 immediate release capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT03464058
Drug: BOS172767 matching placebo capsules
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT03464058
Drug: BOS172767 matching placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01455428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 300 mg/d, BID, 8 weeks treatment
Trial: NCT01062451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment daily.
Trial: NCT01269541
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
RxNorm normalized name: clindamycin Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
Trial: NCT00555841
Drug: ALC and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALC and Placebo
Trial: NCT04497701
Drug: PEG-rhG-CSF group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
Trial: NCT04497701
Drug: rhG-CSF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
Trial: NCT02200822
Drug: beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02756624
Drug: AC-170 0.24%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01154634
Drug: AZD2516, 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral
Trial: NCT01154634
Drug: AZD2516, 16 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral
Trial: NCT01154634
Drug: AZD2516, 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral
Trial: NCT01154634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral
Trial: NCT02194621
Drug: Total Flavor option 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
Trial: NCT02194621
Drug: Total Flavor option 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
Trial: NCT00478972
Drug: placebo (for Rimonabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT01901471
Drug: Single bolus of Placebo of CicloMulsion® (Neurovive).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes.
Trial: NCT01729598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule without active study medication in identical capsules as experimental medicine.
Trial: NCT03017703
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no